Loading [Contrib]/a11y/accessibility-menu.js
JHEOR

Endocrine Diseases

Are Trends in Economic Modeling of Pediatric Diabetes Mellitus up to Date with the Clinical Practice Guidelines and the Latest Scientific Findings?
February 03, 2025 EDT
Are Trends in Economic Modeling of Pediatric Diabetes Mellitus up to Date with the Clinical Practice Guidelines and the Latest Scientific Findings?
Roque Cardona-HernandezAlberto de la Cuadra-GrandeJulen MonjeMaría EchaveItziar OyagüezMaría ÁlvarezIsabel Leiva-Gea

This study aimed to identify whether economic modeling approaches in diabetes in pediatric patients align with the recommendations of clinical practice guidelines and the latest scientific evidence.

We Are on the Verge of Breakthrough Cures for Type 1 Diabetes, but Who Are the 2 Million Americans Who Have It?
November 12, 2024 EDT
We Are on the Verge of Breakthrough Cures for Type 1 Diabetes, but Who Are the 2 Million Americans Who Have It?
Rebecca SmithSamara EisenbergAaron Turner-PhiferJacqueline LeGrandSarah PincusYousra OmerFei WangBruce Pyenson

Healthcare claims data sets were used to estimate the current US population with T1DM and investigate geographic nuances in prevalence and incidence, patient demographics, insurance coverage, and device use.

Cost Savings and Reduced Health Care Utilization Associated with Participation in a Digital Diabetes Prevention Program in an Adult Workforce Population
August 18, 2020 EDT
Cost Savings and Reduced Health Care Utilization Associated with Participation in a Digital Diabetes Prevention Program in an Adult Workforce Population
Cynthia Castro SweetCarolyn Bradner JasikAmy DieboldAshley DuPuisBryan Jendretzke

This study examines the impact of a digital Diabetes Prevention Program (DPP) on reducing all-cause health care costs and utilization among 2027 adult participants at 12 months.

A Pragmatic Clinical Trial to Compare the Real-World Effectiveness of V-Go versus Standard Delivery of Insulin in Patients with Advanced Type 2 Diabetes
March 27, 2019 EDT
A Pragmatic Clinical Trial to Compare the Real-World Effectiveness of V-Go versus Standard Delivery of Insulin in Patients with Advanced Type 2 Diabetes
Mark J. CzirakyScott AbbottMatt NguyenKay LarholtElizabeth ApgarThomas WasserPoul StrangeLeon ShiH. Courtenay HarrisonBeverly EverittLynn Nowak

Many patients with type 2 diabetes mellitus (T2DM) do not have adequate glycemic control, leading to poor patient outcomes and high healthcare costs.

August 22, 2018 EDT
Cost-effectiveness of Simple Insulin Infusion Devices Compared to Multiple Daily Injections in Uncontrolled Type 2 Diabetics in the United States Based on a Simulation Model
Peter WahlqvistJay WarnerRobert Morlock

We assess at what price one such simple insulin infusion device, PAQ®, may be cost-effective compared to MDI in people with T2D not in glycemic control.

February 20, 2018 EDT
Impact of a Novel Insulin Management Service on Non-insulin Pharmaceutical Expenses
John E. SchneiderAnjani ParikhIvana Stojanovic

This study examined the use of insulin management services to enable patients to optimize insulin dosing to achieve HbA1c targets and subsequently reduce health care costs.

Patient Preference for Once-Weekly Dosing in Type 2 Diabetes Mellitus in Japan
March 18, 2016 EDT
Patient Preference for Once-Weekly Dosing in Type 2 Diabetes Mellitus in Japan
Rohini SenAlan L. ShieldsKoichiro Atsuda

This study aims to identify subgroups and patient characteristics correlated with a preference for QW dosing of oral medications for T2DM compared to daily dosing using survey-based methods.

How Do Diabetes Models Measure Up? A Review of Diabetes Economic Models and ADA Guidelines
December 16, 2015 EDT
How Do Diabetes Models Measure Up? A Review of Diabetes Economic Models and ADA Guidelines
Lindsay GovanOlivia WuRobert LindsayAndrew Briggs

We present an overview of published diabetes models with a focus on how well the models are described in relation to the considerations described by the American Diabetes Association guidelines.

Cost Effectiveness of Insulin Glargine versus Neutral Protamin Hagedorn Insulin in the Treatment of Type 2 Diabetes Patients in Turkey
August 15, 2013 EDT
Cost Effectiveness of Insulin Glargine versus Neutral Protamin Hagedorn Insulin in the Treatment of Type 2 Diabetes Patients in Turkey
Ilhan SatmanHayley BennettCandeger YilmazSazi ImamogluGoksun AyvazAbdurrahman ComlekciDemet OzkayaToros Sahin

To evaluate the cost-effectiveness of insulin glargine compared to NPH insulin in patients with T2DM in Turkey, from a Social Security Institution perspective.

This website uses cookies

We use cookies to enhance your experience and support COUNTER Metrics for transparent reporting of readership statistics. Cookie data is not sold to third parties or used for marketing purposes.